Advancements in gene transfer-based therapy for hemophilia A

作者：Doering Christopher B^*; Spencer H Trent

来源：Expert Review of Hematology, 2009, 2(6): 673-683.

DOI：10.1586/EHM.09.63

• adeno-associated virus
• adenovirus
• factor VIII
• gene therapy
• hematopoietic stem cell transplantation
• hemophilia A
• lentivirus
• oncoretrovirus
• transposon
• viral vector

Gene therapy has promised clinical benefit to those suffering with hemophilia A, but this benefit has not yet been realized. However, during the past two decades, basic and applied gene therapy research has progressed and the goal of gene therapy for hemophilia A is once again in our sights. The hemophilia A patient population suffers from a disease that requires invasive, lifelong management, is exorbitantly expensive to treat, has geographically limited treatment access and can become untreatable due to immune reactions to the treatment product. Subsequent to the cloning of the factor VIII gene and cDNA in the early 19805, academic and commercial research laboratories began to pursue gene transfer-based therapies to supplement or supplant the available protein replacement therapy. However, to date, clinical trials for gene therapy of hemophilia A have been unsuccessful. Three trials have been conducted with each having tested a different gene-transfer strategy and each demonstrating that there is a considerable barrier to achieving sustained expression of therapeutic amounts of factor VIII. Recent progress has been made in gene-transfer technology and, relevant to hemophilia A, towards increasing the biosynthetic efficiency of factor VIII. These advances are now being combined to develop novel strategies to treat and possibly cure hemophilia A.

• 出版日期2009-12